EYPT - EyePoint Pharmaceuticals misses top and bottom line estimates

2023-08-02 07:11:00 ET

• EyePoint Pharmaceuticals press release ( NASDAQ: EYPT ): Q2 GAAP EPS of -$0.61 misses by $1.18 .
• Revenue of $9.1M (-21.6% Y/Y) misses by $33.03M .

• Net product revenue for the second quarter was $5.3 million, compared to net product revenues for the second quarter ended June 30, 2022 of $11.3 million. The decline in net product revenue resulted from the sale of the YUTIQ franchise in May 2023 and the discontinuation of DEXYCU sales activities in 2023.

• Net revenue from royalties and collaborations for the second quarter ended June 30, 2023 totaled $3.8 million compared to $0.3 million in the corresponding period in 2022.

• Cash and investments at June 30, 2023 totaled $142.5 million compared to $144.6 million at December 31, 2022.

For further details see: